BioNTech Stock Soars 10% on Breakthrough Cancer Drug Results!
Big news in the biotech world! BioNTech’s stock surged 10% this past Friday after their cancer drug BNT323/DB-1303 delivered stellar results in a Phase III trial for HER2-positive unresectable or metastatic breast cancer. Conducted in China by partner Duality Biotherapeutics, the trial hit its primary endpoint of progression-free survival, outperforming Roche’s trastuzumab emtansine (T-DM1).
Duality Biotherapeutics$DUALITYBIO-B(09606)$ , holding commercial rights in China, is now gearing up to submit a Biologics License Application to China’s NMPA. Meanwhile, BioNTech, with global rights outside China, is running a global Phase III trial for HER2-low metastatic breast cancer. Exciting times ahead! Speaking of hot stocks, Duality Biotherapeutics went public in April, skyrocketing 116% on debut with a closing price of HK$205. Fast forward four and a half months, and their stock hit a jaw-dropping HK$406—doubling from the IPO price! With big-name cornerstone investors backing them, it’s clear Hong Kong’s market is brimming with hidden gems worth digging into.
@TigerPM @TigerObserver @Tiger_comments @Daily_Discussion @TigerStars
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- Enid Bertha·2025-09-08TOPThis positive news does not bring any revenue to BNTX. The only excitement is it brings hope for its future international studies to correlate. But BNTX stock is very inflated nowLikeReport
- glitzii·2025-09-08This sounds like an incredible development1Report
- Mortimer Arthur·2025-09-08Let's go to 1501Report